Skip to main content

Table 3 Antipsychotics taken by subjects including those in the incidence study at baseline and endpoint

From: Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study

Medications

Number (%) of subjects taking at baseline (N = 44)

Number of subjects lost to follow-up (N = 9)

Number (%) of subjects taking at endpoint (N = 35)a

High-potency conventional antipsychoticsb

12 (27.3)

2

4 (11.4)

Medium-potency conventional antipsychoticsc

4 (9.1)

1

4 (11.4)

Low-potency conventional antipsychoticsd

5 (11.4)

2

5 (14.3)

Clozapine

5 (11.4)

2

7 (20.0)

Olanzapine

3 (6.8)

1

5 (14.3)

Risperidone

14 (31.8)

1

13 (37.1)

Sertindole

1 (2.3)

0

12 (34.3)

  1. aIncluding 7 patients developing metabolic syndrome and 28 patients not developing metabolic syndrome.
  2. bHigh-potency conventional antipsychotics including haloperidol and trifluoperazine.
  3. cMedium-potency conventional antipsychotics including clopenthixol and perphenazine.
  4. dLow-potency conventional antipsychotics including chlorpromazine and thioridazine.